ISCONOVA AB
Isconova AB is an R&D company that develops and commercializes adjuvants and vaccines. It provides its adjuvants for veterinary and human vaccines for an enhanced immune reaction with longer duration. The products of the company includes Matrix-M, which is a cell-mediated and an antibody mediated immune response for use in vaccines for humans, dogs, and cats. Matrix-C vaccines are used for horses and Matrix-Q vaccines are used for cows and fishes. Matrix-F is also used for fishes. It also offers AbISCO research reagents, including AbISCO-100 for use in saponin sensitive animal species, such as mice. Isconova AB is a Sweden-based company that was founded in 1999. The company was acquired by Novavax AB on June, 2013.
ISCONOVA AB
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical
Founded:
1999-01-01
Address:
Uppsala, Uppsala Lan, Sweden
Country:
Sweden
Total Employee:
11+
Status:
Active
Total Funding:
5 M USD
Similar Organizations
P4ML
Personalized medicine
Investors List
Innovations Kapital
Innovations Kapital investment in Venture Round - Isconova AB
More informations about "Isconova AB"
Isconova AB - Crunchbase Company Profile & Funding
Isconova AB is an R&D company that develops and commercializes adjuvants and vaccines. It provides adjuvants for veterinary and human vaccines for an enhanced immune reaction with …See details»
Isconova AB - Funding, Financials, Valuation & Investors
Isconova AB is a research and development firm that develops and commercializes adjuvants and vaccines. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Committed to making a difference in Sweden | Novavax
In pursuit of a better adjuvant technology to use with its protein vaccine candidates, Novavax, Inc. acquired Isconova in 2013 and became the company Novavax AB. The acquisition of …See details»
Novavax - Company info. interviews, news - BiopharmaTrend
Novavax AB (formerly Isconova) has its origin at the Swedish University of Agricultural Science (SLU) in Uppsala, where the ISCOM technology was invented by Professor Bror Morein and …See details»
Novavax, Inc. completed the acquisition of Isconova AB (OM:ISCO) …
Jul 31, 2013 Novavax, Inc. made an offer to acquire Isconova AB from InnKap IV managed by InnovationsKapital, Farstop Gard, LMK Ventures AB, LMK Forward AB, Peter Ragnarsson and …See details»
Note 4 - Acquisition of Isconova AB - SEC.gov
Note 4 - Acquisition of Isconova AB. On July 31, 2013 (the "acquisition date"), Novavax announced the acquisition of Isconova (the "Acquisition") pursuant to its public tender offer to …See details»
Isconova - Company Profile - Tracxn
Isconova - Vaccine Adjuvants for Infectious DIseases and Veterinary Markets. Acquired by Novavax. Raised a total funding of $5.02M over 1 round from 1 investor.See details»
Isconova Secures 30 Million Swedish Kronor Growth Financing
Jun 27, 2008 Isconova AB, announced today that it has secured financing of 30 million Swedish kronor ( 3,3 m€ ) from InnovationsKapital, a leading Nordic venture capital firm, and a group of …See details»
Novavax acquires Isconova AB - 2013-12-02 - Crunchbase
Isconova AB Isconova AB is a research and development firm that develops and commercializes adjuvants and vaccines. Acquiring Organization: Novavax Novavax is a biotechnology …See details»
Isconova AB full company profile on Creditsafe
Find up to date company insights for Isconova AB. Get Contact details, financial insights, industry benchmarks, competitors from creditsafe.comSee details»
Novavax makes public offer to acquire Sweden's Isconova for …
Jun 7, 2013 Isconova is a leading international company focused on the development of saponin-based, immune-modulating adjuvants that work with vaccine antigens to promote the …See details»
Novavax makes $30M bid for adjuvant business - Fierce Pharma
Jun 5, 2013 Isconova employs 23 full-time equivalents and has production in place for Phase I and II trial materials. With several early-phase trials already underway, Isconova is planning …See details»
Isconova AB - Company Profiles - BCIQ
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, …See details»
Isconova AB - Crunchbase
Isconova AB is a research and development firm that develops and commercializes adjuvants and vaccines.See details»
ISCONOVA AB innovation strategy - GoodIP
ISCONOVA AB has a total of 48 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Canada, WIPO (World Intellectual Property Organization) and …See details»
Isconova AB Fundamental Company Report Including Financial, …
Isconova AB Fundamental Company Report provides a complete overview of the company’s affairs. [email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ | …See details»
Novavax, Inc. made an offer to acquire Isconova AB (OM:ISCO) …
Jun 4, 2013 Novavax, Inc. made an offer to acquire Isconova AB from InnKap IV managed by InnovationsKapital, Farstop Gard, LMK Ventures AB, LMK Forward AB, Peter Ragnarsson and …See details»
Isconova AB - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Isconova AB . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 12. About. Isconova AB is …See details»
Novavax - Wikipedia
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists …See details»
Novavax - Crunchbase Company Profile & Funding
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious …See details»